I medici

Prof. Dr. med.
Andreas Cerny

Formazione

Laurea in medicina
1981

Specializzazione

Medicina farmacologica
2004
Malattie infettive
1999
Medicina interna generale
1991

Ruolo

Specialista in medicina farmacologica, malattie infettive e medicina interna generale
Medico accreditato

Affiliazioni

Fedeazione dei medici svizzeri (FMH)

Anno di nascita

1956

Inizio attività in clinica

2007

Contatto

Per l’ospedalizzazione di un paziente o per richiedere documentazione medica
T+ 41 91 960 87 12
andreas.cerny@moncucco.ch
segretariato.medico@moncucco.ch

Contatto studio privato

Per fissare un appuntamento o contattare il medico
T+ 41 91 960 85 03

Lingue

Italiano
Tedesco
Francese
Inglese

Altre attività

Direttore, Epatocentro Ticino
Medico consulente, Ospedale Regionale di Locarno
Libera docenza in medicina interna presso l'Università di Berna
Professore Università di Berna, 2002
Sonografia
Pratica di laboratorio

Pubblicazioni

Giudici F, Bertisch B, Negro F, Stirnimann G, Müllhaupt B, Moradpour D, Cerny A, Keiser O; Swiss Hepatitis C Cohort Study. Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach. J Viral Hepat. Mar 23. doi: 10.1111/jvh.12535. [Epub ahead of print] 2016.
Impact of common risk factors of fibrosis progression in chronic hepatitis C. Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, Moradpour D, Cerny A, Malinverni R, Booth DR, Suppiah V, George J, Argiro L, Halfon P, Bourlière M, Talal AH, Jacobson IM, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Negro F. Gut. Oct;64(10):1605-15. 2015.
Terczynska-Dyla E, Bibert S, Duong FH, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Malinverni R, Mangia A, Moradpour D, Müllhaupt B, Negro F, Santoro R, Semela D, Semmo N; Swiss Hepatitis C Cohort Study Group, Heim MH, Bochud PY, Hartmann R. Corrigendum: reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun. Jun 29;6:7280. 2015.
Wang H, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery SM, Filomena A, Wolz OO, Schneiderhan-Marra N, Löffler MW, Wiese M, Pichulik T, Müllhaupt B, Semela D, Dufour JF, Bochud PY, Bowie AG, Kalinke U, Berg T, Weber AN; East-German and Swiss Hepatitis C Virus Study Groups.A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. Hepatology. Nov;62(5):1375-87. 2015
Survival of hepatocellular carcinoma patients is significantly improving: a population- based study from southern Switzerland. Bordoni A, Cerny A, Bihl F, Alerci M, Mazzola P, Peverelli S, Marini G, Majno P, Mazzucchelli L, Spitale A. Cancer Epidemiol. Dec;38(6):679-85. 2014
Terczyńska-Dyla E, Bibert S, Duong FH, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Malinverni R, Mangia A, Moradpour D, Müllhaupt B, Negro F, Santoro R, Semela D, Semmo N; Swiss Hepatitis C Cohort Study Group, Heim MH, Bochud PY, Hartmann R. Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun. Dec 23;5:5699. 2014
Morard I, Clément S, Calmy A, Mangia A, Cerny A, De Gottardi A, Gorgievski M, Heim M, Malinverni R, Moradpour D, Müllhaupt B, Semela D, Pascarella S, Bochud PY, Negro F; Clinical significance of the CCR5 delta 32 allele in hepatitis C. Swiss Hepatitis C Cohort Study Group. PLoS One. Sep 5;9(9):e106424. 2014
C. Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, Moradpour D, Cerny A, Malinverni R, Booth DR, Suppiah V, George J, Argiro L, Halfon P, Bourlière M, Talal AH, Jacobson IM, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Negro F. Impact of common risk factors of fibrosis progression in chronic hepatitis Gut. Sep 11. pii: gutjnl-2014-306997. 2014
S, Marini G, Majno P, Mazzucchelli L, Spitale A. Survival of hepatocellular carcinoma patients is significantly improving: a population-based study from southern Switzerland. Bordoni A, Cerny A, Bihl F, Alerci M, Mazzola P, Peverelli. Cancer Epidemiol. Dec;38(6):679-85. 2014
Frei P, Leucht AK, Held U, Kofmehl R, Manser CN, Schmitt J, Mertens J, Rau M, Baur K, Gerlach T, Negro F, Heim M, Moradpour D, Cerny A, Dufour JF, Müllhaupt B, Geier A; on behalf of the Swiss Hepatitis C Cohort Study Group. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon alfa and ribavirin in chronic hepatitis C virus patients. Liver Int. Apr;34(4):551-7. 2013
Fretz R, Negro F, Bruggmann P, Lavanchy D, De Gottardi A, Pache I, Masserey Spicher V, Cerny A. Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection. Swiss Med Wkly. 17;143: 2013
Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Müllhaupt B, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY; Hiroshima Liver Study Group; Swiss Hepatitis C Cohort Study Group. Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. PLoS One. 29;8(5) 2013
Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FH, Gerlach T, Malinverni R, Moradpour D, Negro F, Müllhaupt B, Bochud PY; Swiss Hepatitis C Cohort Study. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med. 3;210(6):1109-16; 2013
Lange CM, Bibert S, Dufour JF, Cellerai C, Cerny A, Heim MH, Kaiser L, Malinverni R, Müllhaupt B, Negro F, Semela D, Moradpour D, Kutalik Z, Bochud PY; Swiss Hepatitis C
Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme R, Arastéh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M, Kukolj G, Böcher W, Steffgen J. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol. 57(1):39-46; 2012
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA ; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. Apr 12;366(15):1404-13. 2012.
Girardin F, Daali Y, Gex-Fabry M, Rebsamen M, Roux-Lombard P, Cerny A, Bihl F, Binek J, Moradpour D, Negro F, Desmeules J; Swiss Hepatitis C Cohort Study Group. Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. J Viral Hepat. Aug;19(8):568-73. 2012
Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhoop K, Bojunga J, Sarrazin C, Zeuzem S, Müller T, Berg T, Bochud PY, Moradpour D; Swiss Hepatitis C Cohort Study Group. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One.;7(7) 2012
Kuske L, Mensen A, Müllhaupt B, Negro F, Semela D, Moradpour D, Malé PJ, Heim MH, Malinverni R, Cerny A, Dufour JF; Swiss Hepatitis C Cohort Study. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. Swiss Med Wkly. Aug 6;142, 2012
Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhoop K, Bojunga J, Sarrazin C, Zeuzem S, Müller T, Berg T, Bochud PY, Moradpour D, Swiss Hepatitis C Cohort Study Group. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One.;7(7) 2012
Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Frei P, Seifert B, Bischoff Ferrari HA, von Eckardstein A, Müllhaupt B, Geier A; Swiss Hepatitis C Cohort Study Group.The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated- interferon/ribavirin-based therapy in chronic hepatitis C patients. Antivir Ther.;17(3):541- 7. 2012
Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Müllhaupt B, Semela D, Dufour JF, Heim MH, Moradpour D, Cerny A, Malinverni R, Hirsch H, Martinetti G, Suppiah V, Stewart G, Booth DR, George J, Casanova JL, Bréchot C, Rice CM, Talal AH, Jacobson IM, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud PY, Abel L; Swiss Hepatitis C Cohort Study Group; International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group.Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology. Nov;143(5):1244- 52, 2012
Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme R, Arastéh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M,
Wölk B, Trautwein C, Büchele B, Kersting N, Blum HE, Rammensee HG, Cerny A, Stevanovic S, Moradpour D, Brass V. Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands. PLoS One.;7(1) 2012
Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, Goossens N, Kuske L, Müllhaupt B, Gerlach T, Heim MH, Moradpour D, Cerny A, Malinverni R, Regenass S, Dollenmaier G, Hirsch H, Martinetti G, Gorgiewski M, Bourlière M, Poynard T, Theodorou I, Abel L, Pol S, Dufour JF, Negro F; on behalf of the Swiss Hepatitis C Cohort Study Group the ANRS HC EP 26 Genoscan Study Group. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology. Feb;55(2):384-94, 2012
Nicolosi Guidicelli S, Lopez-Guillermo A, Falcone U, Conconi A, Christinat A, Rodriguez- Abreu D, Grisanti S, Lobetti-Bodoni C, Piffaretti JC, Johnson PW, Mombelli G, Cerny A, Montserrat E, Cavalli F, Zucca E. Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group. Hematol Oncol. Sep;30(3):137-42. 2012
Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, Dufour JF, Gerlach TJ, Heim MH, Malinverni R, Müllhaupt B, Negro F, Moradpour D, Bochud PY; Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-α and ribavirin therapy.The Swiss Hepatitis C Cohort Study Group. Hepatology. Apr;55(4):1038-47, 2012
Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY; On Behalf Of The Swiss Hepatitis C Cohort Study Group.Viral Genotype-Specific Role of PNPLA3, PPARG, MTTP and IL28B in Hepatitis C Virus-Associated Steatosis. J Hepatol. Sep;55(3):529-35. 2011
Adami M, Marsteller I, Mazzucchelli L, Cerny A, Bernasconi E, Bertoli R. Granulomatous hepatitis after intravesical bacillus Calmette-Guérin treatment. Scand J Infect Dis. Jan;43(1):55-7. 2011
Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R; SUCCESS Study Investigators. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. Oct;52(4):1201-7. 2010